The price-to-earnings ratio for Sanofi ADR (NASDAQ: SNY) is above average at 20.59x. The 36-month beta value for SNY is also noteworthy at 0.47. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for SNY is 2.44B, and at present, short sellers hold a 0.18% of that float. The average trading volume of SNY on July 03, 2025 was 2.66M shares.
SNY) stock’s latest price update
The stock price of Sanofi ADR (NASDAQ: SNY) has jumped by 0.53% compared to previous close of $49.05. Despite this, the company has seen a gain of 3.16% in its stock price over the last five trading days. prnewswire.com reported 2025-07-02 that NEW YORK, July 2, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SNY’s Market Performance
Sanofi ADR (SNY) has seen a 3.16% rise in stock performance for the week, with a 0.24% gain in the past month and a -9.26% plunge in the past quarter. The volatility ratio for the week is 1.34%, and the volatility levels for the past 30 days are at 1.34% for SNY. The simple moving average for the past 20 days is 0.64% for SNY’s stock, with a -5.69% simple moving average for the past 200 days.
Analysts’ Opinion of SNY
Many brokerage firms have already submitted their reports for SNY stocks, with Exane BNP Paribas repeating the rating for SNY by listing it as a “Outperform.” The predicted price for SNY in the upcoming period, according to Exane BNP Paribas is $65 based on the research report published on April 15, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see SNY reach a price target of $65. The rating they have provided for SNY stocks is “Neutral” according to the report published on March 21st, 2025.
SNY Trading at -3.07% from the 50-Day Moving Average
After a stumble in the market that brought SNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.97% of loss for the given period.
Stock Fundamentals for SNY
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.71 for the gross margin
The net margin for Sanofi ADR stands at 0.14. The total capital return value is set at 0.08. Equity return is now at value 7.34, with 4.29 for asset returns.
Based on Sanofi ADR (SNY), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is 13.25.
Currently, EBITDA for the company is 11.03 billion with net debt to EBITDA at 1.29. When we switch over and look at the enterprise to sales, we see a ratio of 2.63. The receivables turnover for the company is 97.93for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
In summary, Sanofi ADR (SNY) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
